ReviewCell death discovery2025
Efficacy of glucocorticoids treatment in recurrent embryo implantation failure.
Review in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Optimizing the Endometrial Factor in Recurrent Implantation Failure: From Established Diagnostics to Mechanism-Informed Management.Journal of clinical medicine · 2026Review
- Beyond Antibiotics: Traditional Chinese Medicine and Flavonoids in the Management of Endometritis.Veterinary sciences · 2026Review
- Peri-Transfer Glucocorticoid Therapy in Oocyte-Donation IVF Bridging the Immunological Gap.International journal of molecular sciences · 2026Review
- Timing of dexamethasone initiation during controlled ovarian stimulation and live birth after IVF/ICSI: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Editorial: Cellular micro-environment of the endometrium: reproduction, embryo implantation, and placentation - from bench to bedside and beyond to tissue engineering.Frontiers in cell and developmental biology · 2026Article
- Regulatory T cells in human pregnancy: mechanisms, dysregulation, and therapeutic perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Recurrent implantation failure (RIF) poses a significant challenge in treating infertility. RIF can stem from various factors, commonly involving immune issues. Recent literature suggests that glucocorticoids (GCs) can effectively inhibit immune responses in RIF patients. However, a recent multicenter randomized controlled trial found that oral prednisone did not enhance live birth rates in RIF cases. Despite their potential benefits, the diversity in dosage regimens and treatment protocols highlights the need for further research to establish standardized guidelines and ensure long-term safety. This review explores the use of GCs treatments for RIF, including their use alone and in combination with other medications. It emphasizes the necessity for solid evidence to determine the effectiveness and safety of these treatments. Future studies should focus on defining optimal dosages, treatment durations, and administration methods tailored to different RIF patient profiles. Moreover, well-designed randomized trials are crucial to assess the efficacy and risks associated with GCs in treating RIF.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.